SCHEMBL5137326

SCHEMBL5137326

CCCCn1c(CN(CCc2ccccc2F)Cc2ccc3c(c2)OCO3)cnc1-c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.53
HTR2A P28223 2/20 0.44
HTR2C P28335 2/20 0.44
HTR2B P41595 2/20 0.44
TP53 P04637 3/20 0.42
POLB P06746 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
TSHR P16473 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
LMNA P02545 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CTSL P07711 2/20 0.39
PPARG P37231 1/20 0.39
PPARA Q07869 1/20 0.39
HSP90AA1 P07900 1/20 0.38
HSP90AB1 P08238 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5150126 0.95 C5AR1 (0.47) C5AR1HTR2AHTR2CHTR2BTP53
SCHEMBL5137872 0.94 C5AR1 (0.51) C5AR1HTR2AHTR2CHTR2BTP53
SCHEMBL5137108 0.93 C5AR1 (0.52) C5AR1HTR2AHTR2CHTR2BTP53
SCHEMBL5134942 0.93 C5AR1 (0.55) C5AR1HTR2AHTR2CHTR2BTP53
SCHEMBL5135655 0.92 C5AR1 (0.54) C5AR1HTR2AHTR2CHTR2BTP53
SCHEMBL5136535 0.92 C5AR1 (0.57) C5AR1HTR2AHTR2CHTR2BTP53
SCHEMBL4766677 0.91 C5AR1 (0.56) C5AR1HTR2AHTR2CHTR2BTP53
SCHEMBL5135316 0.90 C5AR1 (0.53) C5AR1HTR2AHTR2CHTR2BTP53
SCHEMBL4765554 0.90 C5AR1 (0.59) C5AR1HTR2AHTR2CHTR2BTP53
SCHEMBL4770879 0.90 C5AR1 (0.59) C5AR1HTR2AHTR2CHTR2BTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed